CytoDyn Announces Settlement with Amarex Clinical Research LLC
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company's balance sheet
26 days ago - GlobeNewsWire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
5 weeks ago - GlobeNewsWire
CytoDyn to Host Webcast to Provide Company Update
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
2 months ago - GlobeNewsWire
May 2024 Letter to Shareholders
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (...
2 months ago - GlobeNewsWire
CytoDyn Announces FDA Has Lifted Clinical Hold
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing ...
5 months ago - GlobeNewsWire
CytoDyn Announces Submission of Clinical Protocol to FDAand Initiation of Pre-Clinical Study in Glioblastoma
VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
6 months ago - GlobeNewsWire
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
6 months ago - GlobeNewsWire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY)
NEW YORK , Jan. 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CytoDyn Inc. (OTC: CYDY) on behalf of the company's shareholders. The investigation seeks to determ...
7 months ago - PRNewsWire
CytoDyn Announces Webcast to Provide Company Update
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
8 months ago - GlobeNewsWire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
9 months ago - GlobeNewsWire
November 2023 Letter to Shareholders
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the C...
9 months ago - GlobeNewsWire
CytoDyn Announces Company Updates and Investment Community Update Webcast
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24 th , 2023, at 1 PM PT / 4 PM ET V...
1 year ago - GlobeNewsWire
CytoDyn Announces President Takes Medical Leave of Absence
Antonio Migliarese assumes interim President role Dr. Melissa Palmer appointed interim Chief Medical Officer Dr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor
1 year ago - GlobeNewsWire
CytoDyn to Hold Webcast to Provide a Company Update
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...
1 year ago - GlobeNewsWire
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
1 year ago - GlobeNewsWire
Former CytoDyn CEO and clinical trial associate indicted for defrauding investors
The U.S. Department of Justice will prosecute the former CEO of Vancouver, Wash.-based biotech company CytoDyn, Nader Pourhassan, and an associate for allegedly defrauding investors.
1 year ago - GeekWire
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
1 year ago - GlobeNewsWire
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
Company to complete and submit responses to FDA clinical hold
1 year ago - GlobeNewsWire
CytoDyn Announces Appointment of Additional Directors with Industry Experience
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board
1 year ago - GlobeNewsWire
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...
2 years ago - GlobeNewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY
New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCQB: CYDY). Such investors are adv...
2 years ago - Newsfile Corp
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Compan...
2 years ago - Business Wire
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President
VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
2 years ago - GlobeNewsWire
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV
2 years ago - GlobeNewsWire
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer
VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
2 years ago - GlobeNewsWire
